




touchREVIEWS

in Oncology & Haematology

VOLUME 22 • ISSUE 2 • 2026

EDITOR-IN-CHIEF: AXEL S MERSEBURGER

Where are we now: Clinical utility and challenges of circulating tumor DNA in breast cancer

Saumya Easaw, Antoinette RTan and Arielle L Heeke

Choosing the appropriate adjuvant therapy in patients with melanoma undergoing neoadjuvant treatment

Gabriela Franco Katz, Beatriz Mendes Awni Cidale, Ana Zélia Leal Pereira, Alline Guimarães de Castro, Giulia Kodja Zanetta, Gustavo Benfatti Olivato and Rodrigo Ramella Munhoz

Emerging evidence of trophoblast cell-surface antigen 2-targeting antibody–drug conjugates in metastatic triple-negative breast cancer: A review


Hidenobu Nakagama and Toshinari Yamashita

www.touchONCOLOGY.com

touchREVIEWS in Oncology & Haematology

Volume 22 • Issue 2 • 2026

Cover image: 3d rendered medically accurate illustration of leukocytes attacking a cancer cell
By Sebastian Kaulitzki# | © stock.adobe.com



touchREVIEWS in Oncology & Haematology wishes to thank the organizations below for their assistance. This does not constitute any official endorsement.



Senior Editorial Director
Gina Furnival

Editorial Directors
Katey Gabrysch
Carla Junkier
Sophie Nickelson

Commissioning Editor
Victoria Jones

Editorial Workflow
Heather Hall

Head of Content & Communications
Nicola Cartridge
E: nicola.cartridge@touchmedicalmedia.com
T: +44 (0)20 7193 3186

CEO & Managing Director
Barney Kent
E: barney.kent@touchmedicalmedia.com
T: +44 (0)20 7193 3009

Head of Strategic Partnerships
Caroline Markham
E: caroline.markham@touchmedicalmedia.com
T: +44 (0)20 7193 3704

All information obtained by Touch Medical Media and each of the contributors from various sources is as current and accurate as possible. However, due to human or mechanical errors, Touch Medical Media and the contributors cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions, or for the results obtained from the use thereof. Where opinion is expressed, it is that of the authors and does not necessarily coincide with the editorial views of Touch Medical Media. Statistical and financial data in this publication have been compiled on the basis of factual information and do not constitute any investment advertisement or investment advice. For the avoidance of doubt, the information contained in this publication is intended for use by licensed medical professionals. The content should not be considered medical advice, diagnosis or treatment recommendations.

© 2026 Touch Medical Media Services Limited, a private limited company registered in England and Wales at 3 Stockport Exchange, Stockport, Cheshire, SK1 3GG, UK, with registered number 08197142. All rights reserved. eISSN: 2752-5481



www.touchmedicalmedia.com

touchREVIEWS

in Oncology & Haematology

Editor-in-Chief

Axel S Merseburger

Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany

Matti S Aapro

Multidisciplinary Oncology Institute, Genolier, Switzerland

Eleni Andreopoulou

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Editorial Board

Mohammad Ammad-Ud-Din

Rochester General Hospital, Rochester, NY, USA

Ahmad Awada

Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium

Wadie F Bahou

State University of New York, Stony Brook, NY, USA

Tanios Bekaii-Saab

Mayo Clinic, Phoenix, AZ, USA

Raffaele Califano

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK

Ezra Cohen

University of Chicago Medical Center, Georgetown University, Chicago, IL, USA

Jorge Cortes

Georgia Cancer Center, Augusta University, Augusta, GA, USA

Véronique Diéras

Department of Medical Oncology, Centre Eugène Marquis, Rennes, France

Massimo Dominici

Medical Oncology, University Hospital of Modena, Modena, Italy

Martin J Edelman

Fox Chase Cancer Center, Philadelphia, PA, USA

Bleddyn Edwards

Hywel Dda University Health Board, Haverfordwest, Wales, UK

Dean A. Fennell

Leicester Cancer Research Centre, Genetics & Genome Biology, University of Leicester, UK

Robin Foà

Institute of Hematology, 'La Sapienza' University of Rome, Rome, Italy

Michael K Gibson

Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

Charlie Gourley

Cancer Research UK Edinburgh Center; Nicola Murray Centre for Ovarian Cancer Research, The University of Edinburgh, Scotland, UK

Paolo A Ascierto

Unit of Melanoma, ational Tumor Institute 'Fondazione G Pascale', Naples, Italy

John L Marshall

Lombardi Comprehensive Cancer Center, Washington, DC, USA

Petros Grivas

University of Washington and Seattle Cancer Care Alliance, Washington, WA, USA

Martin Hutchings

The Finsen Centre, National Hospital, Copenhagen University Hospital, Copenhagen, Denmark

Elias Jabbour

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Ken Kato

National Cancer Center Hospital, Tokyo, Japan

Daniel Kelly

Royal College of Nursing, School of Healthcare Sciences, Cardiff University, Cardiff, UK

Ticiana Leal

Emory University School of Medicine, Atlanta, GA, USA

Gabriel Lenz

AdventHealth, Orlando, FL, USA

Charles D Lopez

Oregon Health & Science University, Portland, OR, USA

Domenica Lorusso

Catholic University of Rome, Rome, Italy

Rimas V Lukas

Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA

Mario Mandalà

Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy

Pier Mannuccio Mannucci

Maggiore University Hospital of Milan; Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Milan, Italy

John L Marshall

MedStar Georgetown University Hospital, Washington, DC, USA

Michael J Morris

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Suchita Pakkala

Emory University School of Medicine, Atlanta, GA, USA

Soo Park

University of California San Diego, CA, USA

David G Mutch

Washington University School of Medicine, St Louis, MO, USA

Maurice Péro

Thoracic Oncology, Medical Oncology Department of Léon Bérard Cancer Center, Lyon, France

Bernardo Rapoport

The Medical Oncology Centre of Rosebank, Johannesburg, South Africa

Isabelle Ray-Coquard

Claude Bernard University, Lyon, France

Hannah Russon

Velindre Oncology Academy, Cardiff, Wales, UK

Emma Searle

The Christie Hospital NHS Foundation Trust, Manchester, UK

Lena Sharp

Regional Cancer Center, Stockholm, Sweden

Ana Tecic Vuger

University Hospital Centre Zagreb, Croatia

Bertrand Tombal

Université Catholique de Louvain, Brussels, Belgium

Sara M Tolaney

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Ulka Vaishampayan

Wayne State University, Detroit, MI, USA

Benjamin Weinberg

Ruesch Center for the Cure of Gastrointestinal Cancers; Lombardi Comprehensive Cancer Center, Washington, DC, USA

Antoinette J Wozniak

Wayne State University; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

Toshinari Yamashita

Kanagawa Cancer Center, Yokohama, Japan

touchREVIEWS in Oncology & Haematology

Established: January 2005 Frequency: Bi-annual
Current edition: Volume 22 Issue 2, 2026

Aims and scope

- *touchREVIEWS in Oncology & Haematology* enables time-pressured physicians to stay abreast of major advances and opinions in oncology and haematology practice.
- *touchREVIEWS in Oncology & Haematology* comprises balanced and comprehensive articles written by leading authorities, addressing the most important and salient developments in the oncology and haematology fields.
- *touchREVIEWS in Oncology & Haematology* endeavours to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity. The editorial policy has been designed to encourage discussion among this peer group.
- Comprehensive bibliographies for each article mean that *touchREVIEWS in Oncology & Haematology* is an informative and valuable reference tool for use throughout the year.
- All articles are subject to peer review, and must adhere to the ICJME, GPP 2022, and COPE guidelines.

Structure and format

- *touchREVIEWS in Oncology & Haematology* is a peer-reviewed, free-to-access, bi-annual journal comprising review articles, editorials and original research.
- The structure of each edition of the publication comprises section categories determined by the Editor. The degree of coverage assigned to each category is the decision of the Editor, and in part reflects the views of the Editorial Board.
- All articles state any author disclosures along with any funding, financial support and/or medical writing assistance.
- Each edition of *touchREVIEWS in Oncology & Haematology* is published in full, online at: www.touchONCOLOGY.com

Editorial expertise

touchREVIEWS in Oncology & Haematology is supported by various levels of expertise:

- Guidance from an Editorial Board consisting of leading authorities from a variety of oncology and haematology disciplines.
- Invited contributors who are recognized authorities in their respective fields.
- Peer review – conducted by experts appointed for their experience and knowledge of a specific topic.
- An experienced team of editors and technical editors.

Peer review

- On submission, all articles are assessed by the Editor to determine their suitability for inclusion and appropriateness for peer review.
- The Editor identifies appropriate reviewers, who are selected on the basis of their specialist knowledge in the relevant area, following consultation with a member of the Editorial Board where necessary.
- We aim to have the final peer review decision within 4 weeks.
- Following review, papers are either accepted without modification, returned to the author(s) to incorporate required changes, or not accepted for publication.
- The Editor reserves the right to accept or reject

any proposed amendments on the advice of the Editorial Board and reviewers.

Submissions and instructions for authors

- The Editor commissions articles with guidance from the Editorial Board and unsolicited articles are welcomed.
- The Editor is always keen to hear from authors wishing to discuss potential submissions, and will give due consideration to any proposals. Please contact the Editor for further details: editorialmanager@touchmedicalmedia.com
- Instructions for authors are available on the website: www.touchONCOLOGY.com

Distribution and readership

touchREVIEWS in Oncology & Haematology is distributed globally, on a bi-annual basis, through controlled circulation to senior professionals in the field globally.

Free-to-access

All articles are free-to-access, which allows anyone in the oncology and haematology field to download published articles free of charge.

Abstracting and indexing

touchREVIEWS in Oncology & Haematology is abstracted, indexed and listed in Embase, EBSCO, Genamics JournalSeek, Google Scholar, IndexCopernicus and Summon by Serial Solutions.

Copyright

Authors transfer copyright of their article to Touch Medical Media, who publish the article as free-to-access to registered users.

Online resources

www.touchmedicalmedia.com provides clinicians and other industry professionals with a free resources across nine therapy areas including cardiology, endocrinology, haematology, immunology, infectious diseases, neurology, oncology, ophthalmology and respiratory and pulmonary medicine.


Society partners

touchONCOLOGY has developed very valuable partnerships with the most respected not-for-profit medical societies both in Europe and the USA. These partnerships are key as touchONCOLOGY.com helps to promote awareness of these medical societies whilst also providing free-to-access, peer-reviewed articles and multimedia content to society members, which ensures that the industry is kept up to date with the latest cutting-edge content and opinion from world-renowned doctors.

About Touch Medical Media

Touch Medical Media publishes a rich and diverse portfolio of free-to-access, peer-reviewed journals across the clinical and pharmaceutical arenas. Touch Medical Media aims to assist in the education and practice of healthcare and pharmaceutical professionals. 





Foreword

1 Foreword

Axel Merseburger

Department of Urology, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Germany

Editorials

Breast Cancer

2 Where are we now: Clinical utility and challenges of circulating tumor DNA in breast cancer

Saumya Easaw, Antoinette R Tan and Arielle L Heeke

Department of Solid Tumor Oncology and Investigational Therapeutics, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC, USA

Dermatological Cancers

6 Choosing the appropriate adjuvant therapy in patients with melanoma undergoing neoadjuvant treatment

Gabriela Franco Katz,¹ Beatriz Mendes Awni Cidale,² Ana Zélia Leal Pereira,² Aline Guimarães de Castro,³ Giulia Kodja Zanetta,² Gustavo Benfatti Olivato² and Rodrigo Ramella Munhoz²

1. Chesterfield Royal Hospital, Chesterfield, UK; 2. Oncology Center, Sírio- Libanês Hospital, São Paulo, Brazil; 3. Oncology Center, Sírio- Libanês Hospital, Brasília, Brazil

Reviews

Bladder Cancer

12 Perioperative management of urothelial carcinoma

Amena Ahmad, Oskar Lepiarczyk and Alison Birtle

Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK

Breast Cancer

21 Emerging evidence of trophoblast cell-surface antigen 2-targeting antibody-drug conjugates in metastatic triple-negative breast cancer: A review

Hideobu Nakagama and Toshinari Yamashita

Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan


Gastrointestinal Cancers

27 Contemporary Management of Gastrointestinal Cancers: Advances in Targeted Therapy, Immunotherapy, and Biomarkers

Ahmed Maklad and Rafea Ismael Hakki

College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

Contents



38 The microbiome and mycobiome in esophageal cancer: Implications for pathogenesis, detection and treatment

Margaret Comer,¹ Hubert Chen² and Michael K Gibson^{1,3}

1. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; 2. Vanderbilt University, Nashville, TN, USA; 3. Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt Health, Nashville, TN, USA

Hematological Malignancies

50 Frontline Treatment for Diffuse Large B-Cell Lymphoma in 2026...Lessons from targeted and immune-based approaches

Tyrel Phillips

Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA